1. Introduction {#sec1-pharmaceutics-11-00656}
===============

One of the classical anti-cancer drugs used in solid cancer is cisplatin (cis-diamminedichloroplatinum(II)) (CIS), and this is still commonly used today in numerous oncological treatment regimens. Presenting increased effectiveness with increased dosage, several studies have attempted to reduce the limiting factors of CIS administration, the major one being its inherent nephrotoxicity \[[@B1-pharmaceutics-11-00656],[@B2-pharmaceutics-11-00656],[@B3-pharmaceutics-11-00656]\]. Even though hearing loss, gastro-intestinal problems, and immune suppression are common, these do not pose a limiting factor on platinum salt treatment \[[@B4-pharmaceutics-11-00656],[@B5-pharmaceutics-11-00656]\].

Despite the fact that we live in the age of targeted cancer treatments and the subsequent unpopularity of classical medications such as antifolates and platinum salts, these are still fairly common in practice and finding ways to make them more effective is still a valid area of research. CIS renal toxicity is generally considered to be influenced by several factors, the most notable being the destruction of renal epithelial cells with subsequent loss of kidney function, damaging effects on mtDNA, and also, the activation of apoptosis and necrosis pathways inside the cell. As of now, different strategies to reduce the side effects have been tried, with different levels of success. In day to day clinical practice, salt-based volume expansion is used with added diuretics such as mannitol or furosemide \[[@B6-pharmaceutics-11-00656],[@B7-pharmaceutics-11-00656],[@B8-pharmaceutics-11-00656]\]. Another noteworthy strategy is the administration of Amifostine to treat ovarian cancers, with its protective mechanism still being a debated topic in literature \[[@B9-pharmaceutics-11-00656],[@B10-pharmaceutics-11-00656],[@B11-pharmaceutics-11-00656]\]. Nevertheless, the incomplete success of these approaches has opened the way for combined treatments and the proposal of a few possible new candidates. Our study focuses on one such candidate, a natural grape-based extract from the market.

Numerous in vivo studies have indicated the antioxidant and protective effects of grape juice or grape seed extract, however, the information regarding the protective role of grape pomace extract is limited \[[@B12-pharmaceutics-11-00656],[@B13-pharmaceutics-11-00656],[@B14-pharmaceutics-11-00656]\].

Of the numerous compounds with theorized nephroprotective effects, resveratrol and polyphenols such as phenolic acids present the most promise \[[@B15-pharmaceutics-11-00656]\]. In vivo experimental studies have provided evidence of the nephroprotective effect of resveratrol (a major component in grape juice) on the toxicity induced by drugs or toxins (gentamicin, cyclosporine, cisplatin, arsenic trioxide). The protective mechanisms are mainly related to oxidative stress reduction and nitric oxide modulation \[[@B16-pharmaceutics-11-00656],[@B17-pharmaceutics-11-00656],[@B18-pharmaceutics-11-00656],[@B19-pharmaceutics-11-00656]\].

This study investigated the dose--response effect of grape pomace extract (GE) on CIS-induced renal changes in rats.

2. Materials and Methods {#sec2-pharmaceutics-11-00656}
========================

2.1. Animals {#sec2dot1-pharmaceutics-11-00656}
------------

The animals used in this study were Charles River Wistar (*n* = 64) white male rats with a median weight of 265 ± 15 g. The animals were housed in polysulfone type III-H open-top cages (Tecniplast, Buguggiate, Italy) and had access to filtered tap water in bottles and pelleted feed (Cantacuzino Institute, Bucharest, Romania) ad libitum. The bedding was a standard wood chip aseptic bedding (LignocelVR; J. Rettenmaier & SohneGmBH Co. KG, Rosenberg, Germany). The rats were acquired from the Laboratory Animal Facility of the Iuliu Hatieganu University of Medicine and Pharmacy and were kept at a standard temperature of 20 ± 2 °C and a relative humidity of 55% ± 10%, in a 12:12 h light-dark cycle (lights on from 7 a.m. to 7 p.m.) with a light intensity of 285 lux at 1 m above the floor. The working protocol was revised and approved by the Ethics Committee of the University (no. 112) from 11 May 2018.

Prior to the onset of the study, all animals were quarantined and left to acclimatize to the separation from the rat colony for 2 days. The "Guiding Principles in the Use of Animals in Toxicology", adopted by the Society of Toxicology (USA) and the National Law regarding the protection of animals used for scientific research, were the specific regulations and amendments from this study.

2.2. Grape Extract (GE) {#sec2dot2-pharmaceutics-11-00656}
-----------------------

As per the manufacturer's information, GE contains extracts from grape (*Vitis vinifera*) seeds, rahis and peel (700 mg/mL) in a water-based, homogenous solution. The polyphenolic value of the product is 300 mg gallic acid equivalents (GAE)/mL. For this experiment, we used three bottles of commercially available products, homogenized together in one recipient. Thus, all animals received the same product with the same composition for the entire treatment period, without variability between the active compounds.

We used GE at two different concentrations. The doses were measured in mL/kg body weight (b.w.) and also in mg GAE. The first dose consisted of 0.35 mL/kg b.w. or 105 mg GAE (GEd1), and the second dose was 0.7 mL/kg b.w. or 210 mg GAE (GEd2).

2.3. Experimental Design {#sec2dot3-pharmaceutics-11-00656}
------------------------

A total of 64 rats were randomly divided into eight groups (*n* = 8). In the first 7 days of treatment, each animal received treatment, according to its group. Groups 1 and 4 received 0.9% saline solution, groups 2, 5, and 7 received GEd1, and groups 3, 6, and 8 received GEd2. On the eighth day, groups 4--8 received one intraperitoneal dose of 7.5 mg/kg b.w. CIS. On the next 4 days, groups 7 and 8 received GEd1 or GEd2, according to their previous treatment. On the last day of the study, blood samples were collected from the retroorbital sinus plexus of the rats under mild anesthesia, and then all animals were euthanized using deep anesthesia. Kidneys were removed for the histopathological analysis. After coagulation, the serum was separated by centrifuging at 4000 rpm for 15 min and was kept at −20 °C until further biochemical analysis. ([Figure 1](#pharmaceutics-11-00656-f001){ref-type="fig"})

2.4. Measurements {#sec2dot4-pharmaceutics-11-00656}
-----------------

We measured the mortality percentage for each group. We determined the urea and creatinine levels using spectrophotometry. The CIS plasma concentrations were estimated by using a validated high-throughput liquid chromatography (HPLC) (Agilent Technologies, Santa Clara, CA, USA) analytical method \[[@B20-pharmaceutics-11-00656]\]. A 3 × 100 mm, 3.5 µm Zorbax C 18 chromatographic column (Agilent Technologies) was used for separation. The mobile phase consisted of 80% methanol and 20% water. The flow rate was 1.5 mL/min; the thermostat temperature was set at 25 °C. The peaks were detected by using an Agilent 1100 series UV detector (at 254 nm). The calibration curve was linear over a concentration range of 1--10 µg/mL.

The total antioxidant capacity (TAC) of the GE in vitro and in vivo (after animal administration) was measured according to the method previously described by Erel \[[@B21-pharmaceutics-11-00656]\].

2.5. Histopathological Examination {#sec2dot5-pharmaceutics-11-00656}
----------------------------------

At the end of the study, the kidneys of each animal were removed. Sections of excised kidney tissues from all animals were preserved in 10% formaldehyde, dehydrated in graduated ethanol, and incorporated into paraffin. Thereafter, sections of the liver were cut at 7 μm on a microtome (Leica RM 2145), (Leica Microsystems, Wetzlar, Germany) and mounted on glass slides. Slides were stained with hematoxylin-eosin for histological evaluation. The histological sections were examined under a Leica DM750 microscope, and the images were captured using a Leica ICC 50 HD camera (Leica Microsystems) connected to the microscope.

We determined the renal parenchymal damage with a score based on the tubular necrosis percentage observed in the tissues (0---no damage; 1---isolated unicellular necrosis; 2---tubular necrosis \<25%, 3---tubular necrosis between 25% and 50%; 4---tubular necrosis \>50%).

2.6. Statistical Analysis {#sec2dot6-pharmaceutics-11-00656}
-------------------------

The statistical analysis was done using SPSS 18.0 software (IBM, Armonk, NY, USA). One-way analysis of variance (one-way ANOVA) followed by post hoc testing was performed to detect the differences between groups. *p* \< 0.05 was considered statistically significant.

3. Results {#sec3-pharmaceutics-11-00656}
==========

3.1. Mortality {#sec3dot1-pharmaceutics-11-00656}
--------------

The mortality results are presented in [Table 1](#pharmaceutics-11-00656-t001){ref-type="table"}. Control groups had no deaths in the group, while in the CIS group, 50% of the animals died before the end of the experiment. As a trend, the treated groups had high mortality rates, with the only exception being the group that received pre- and post-treatment with the first dose of CIS (GEd1 + CIS + GEd1).

The high mortality in group 8 (GEd2+CIS+GEd2) influenced the following tests, so we did not include the samples from this group in the final statistical analysis.

3.2. Urea and Creatinine Levels {#sec3dot2-pharmaceutics-11-00656}
-------------------------------

Plasmatic urea and creatinine levels were measured for 7 groups and are displayed in [Figure 2](#pharmaceutics-11-00656-f002){ref-type="fig"}. Measured values were higher in all groups receiving the grape extract, regardless of the dosage or treatment scheme.

3.3. Kidney Histology Examination {#sec3dot3-pharmaceutics-11-00656}
---------------------------------

The scores according to the degree of tubular necrosis are summarized in [Table 2](#pharmaceutics-11-00656-t002){ref-type="table"}.

Renal tissue with normal architecture was observed in the control group ([Figure 3](#pharmaceutics-11-00656-f003){ref-type="fig"}).

The results of the histological analysis are displayed in [Figure 4](#pharmaceutics-11-00656-f004){ref-type="fig"}, [Figure 5](#pharmaceutics-11-00656-f005){ref-type="fig"} and [Figure 6](#pharmaceutics-11-00656-f006){ref-type="fig"}. Extensive degeneration of the tubular epithelium, hyaline casts, interstitial edema, and inflammatory cell infiltration were observed in all groups that received CIS. The mildest tubular necrosis was observed in the group treated with GEd1 before and after the CIS dose.

3.4. CIS Plasmatic Concentration {#sec3dot4-pharmaceutics-11-00656}
--------------------------------

The results for CIS plasmatic concentration did not differ significantly for any of the groups ([Figure 7](#pharmaceutics-11-00656-f007){ref-type="fig"}).

3.5. Total Antioxidant Capacity (TAC) {#sec3dot5-pharmaceutics-11-00656}
-------------------------------------

TAC results were measured in mmol Trolox Equivalents/Liter (TR Eq/L). For the GE, the TAC level was 439.38 mmol TR Eq/L. In the animals, there was no statistically significant difference between the groups. TAC values were lower in the CIS group ([Table 3](#pharmaceutics-11-00656-t003){ref-type="table"}).

4. Discussion {#sec4-pharmaceutics-11-00656}
=============

The ability of CIS to inhibit cancer growth relies on DNA damage and oxidative stress \[[@B22-pharmaceutics-11-00656]\]. The main mechanism of CIS is its ability to inhibit DNA synthesis, cause inter- and intra-strand DNA damage, and repair processes in fast-growing cells \[[@B5-pharmaceutics-11-00656],[@B23-pharmaceutics-11-00656],[@B24-pharmaceutics-11-00656]\].

Furthermore, metals in general and, specifically, platinum compounds are able to generate reactive oxygen species (ROS), which increase its effectiveness and tumor toxicity \[[@B25-pharmaceutics-11-00656]\].

The major drawback of CIS treatment is its high toxicity, which mostly damages the heart and kidneys. CIS enters these tissues where it accumulates and produces its cytotoxic effects via oxidative stress damage, inflammation, and apoptotic pathway activation, leading, in the end, to renal and cardiac failure \[[@B26-pharmaceutics-11-00656],[@B27-pharmaceutics-11-00656],[@B28-pharmaceutics-11-00656]\]. CIS will disrupt the mitochondrial membrane both directly---via CIS binding to its proteins, causing mitochondrial dysfunction and cellular death---and also indirectly---by an ROS-mediated reaction. The subsequent mitochondrial damage intensifies the oxidative stress and cell inflammation \[[@B29-pharmaceutics-11-00656]\].

This shows that the main role in CIS toxicity is the formation of ROS and oxidative stress \[[@B30-pharmaceutics-11-00656]\]. Antioxidants have proven to be a good option against ROS damage and CIS nephrotoxicity, especially when given before CIS treatment \[[@B31-pharmaceutics-11-00656],[@B32-pharmaceutics-11-00656]\]. In our study we determined the TAC. The minimum mean value was observed in the CIS group. This value was 37.5% lower than the mean value of the control group. So, CIS has pro-oxidant capacity. Grape extracts are a known antioxidant dietary supplement, aimed at opposing the effects of ROS \[[@B33-pharmaceutics-11-00656],[@B34-pharmaceutics-11-00656],[@B35-pharmaceutics-11-00656]\]. Regarding such treatments in CIS toxicity, improvements of the renal function of animal models was observed, but at this point, no clear conclusion regarding its beneficial effect has been made \[[@B36-pharmaceutics-11-00656],[@B37-pharmaceutics-11-00656]\]. GE increased the antioxidant capacity, but probably not enough to protect against the overall damage of the chemotherapeutic agent. As mentioned above, there are many mechanisms involved in the side effects of CIS. Moreover, the small number of remaining animals after CIS administration made data interpretation difficult.

In previous studies, the dosages of CIS used in single administration varied from 5 to 10 mg/kg b.w. \[[@B38-pharmaceutics-11-00656],[@B39-pharmaceutics-11-00656]\]. The dose used in our study (7.5 mg/kg b.w.) represents the lethal dose 50 of CIS, and is similar to what Yang et al. reported in their study on female rats \[[@B40-pharmaceutics-11-00656]\].

An unexpected event in our study was the high mortality rate of the animals in the treated groups. In all but one group, the mortality percentages were higher than in the CIS group alone. The lowest mortality rate was in the GEd1-treated group before and after CIS (group 7), while the highest mortality rate was in the GEd2-treated group before and after CIS (group 8). For the other two groups, which were only pre-treated with GEd1 and GEd2, the mortality rate was intermediate but was higher than that of the group treated with CIS alone. These results highlight an increase in CIS toxicity by the GE.

The mean creatinine and urea values in the control group were statistically significantly different from the average values of the groups treated with CIS and GE (*p* \< 0.05). These results are similar to those obtained in previous studies on CIS, but the addition of GE to the CIS treatment had unexpected negative results \[[@B41-pharmaceutics-11-00656]\].

Nephrotoxicity was also revealed by the histopathological examination. In CIS and CIS with GE, severe and extensive degeneration of the tubular epithelium, hyaline castings, interstitial edema, and inflammatory cell infiltration were observed. Tubular necrosis was more important in the groups that received pre-treatment with GEd1 and pre- and post-treatment with GEd2.

Similar to the previous results, the group receiving GEd1 before and after CIS had the lowest tubular necrosis (with patchy, isolated, unicellular necrosis). No histological changes were observed in the groups with GE without CIS. Therefore, nephrotoxicity depends on the interaction between CIS and GE and also on the dose of GE.

Renal CIS uptake is mediated by two membrane transporters, copper transporter 1 and human organic cation transporter 2, which take part in the nephrotoxicity mechanism by stimulating the accumulation of CIS in the renal tissue where it exhibits the stimulation of ROS and oxidative stress \[[@B42-pharmaceutics-11-00656],[@B43-pharmaceutics-11-00656],[@B44-pharmaceutics-11-00656],[@B45-pharmaceutics-11-00656]\]. It is known that the CIS concentration in the proximal convoluted tubule can be up to 5 times greater than in the blood and that the concentration in the kidneys is proportional to the concentration in the blood \[[@B46-pharmaceutics-11-00656]\].

We hypothesised that the negative outcome of the GE treatment was associated with an increase in the renal uptake of CIS. For this, we analyzed the plasmatic CIS concentration to see if there was a concentration change between the treatment groups. Our results showed no significant difference between the plasmatic concentrations of CIS and only a slight decrease for the GE treated groups.

We therefore conclude that GE did not influence the renal intake of CIS and that there is no pharmacokinetic interaction between CIS and the GE.

In order to establish the cause of the high mortality, we examined the possibility that the GE itself might have had a harmful effect. As mentioned before, GE has a potent antioxidant effect. However, previous studies linked GE with pro-oxidant and DNA-damaging properties \[[@B47-pharmaceutics-11-00656]\]. Most of the GE effects are attributed to its rich composition of polyphenols, from which resveratrol is the most abundant and of high importance \[[@B48-pharmaceutics-11-00656]\]. Resveratrol was previously linked to a better outcome in CIS-treated animals and is a potent antioxidant \[[@B15-pharmaceutics-11-00656]\]. Besides its beneficial effects, resveratrol has also been reported as having pro-oxidant and cytotoxic effects. Additionally, gallic acid, another compound of GE, also exhibits pro-oxidant effects \[[@B49-pharmaceutics-11-00656]\].

The TAC results for GE showed a theoretically high free radical scavenging potential and a reduction in oxidative stress. However, the in vivo TAC results showed no significant difference in the redox states of the different studied groups.

Natural products rich in polyphenolic compounds were initially studied initially in vitro and then, some of them were studied in vivo. It has been observed that the in vivo effects do not always correlate with the in vitro ones \[[@B50-pharmaceutics-11-00656]\]. As previously mentioned, the main active beneficial compounds of GE are polyphenols. When characterized in vitro, polyphenols present antioxidative properties that translate into potential health benefits. This changes in vivo, because of the modifications caused by the gastrointestinal tract (by the gastrointestinal enzymes and microflora) and by the liver metabolism \[[@B51-pharmaceutics-11-00656]\].

The data of our study showed that the in vitro antioxidant capacity of pomace GE could not be translated to in vivo antioxidant capacity. The TAC values of the GE groups were not significantly different compared with those of controls ([Table 3](#pharmaceutics-11-00656-t003){ref-type="table"}). A gap between the in vitro and in vivo antioxidant capacity results of grape extracts has been previously observed in other studies \[[@B52-pharmaceutics-11-00656]\].

All being considered, we believe that the toxicity mechanism is not linked to the pro-oxidant effect of these substances, but rather to their DNA-damaging effect.

The exact mechanism of action remains unknown, but a possible toxicity pathway involves the interaction of these substances from the GE with copper ions. This would lead to the synthesis of DNA damaging molecules and also to reactive oxygen radicals and ROS \[[@B53-pharmaceutics-11-00656]\].

On the last electron-shell of the copper ion, there is only one electron present, which makes it vulnerable to electron-exchanging reactions in the body. The same is true for platinum, with only one electron on its last electron-shell. This means the toxic effect was most likely caused by the interaction of resveratrol from the GE with the platinum ions in CIS that accumulated in the kidney. This might have resulted in toxic resveratrol radicals that caused DNA cleavage and thus, the induction of cell death.

5. Limitations {#sec5-pharmaceutics-11-00656}
==============

It is necessary to take into account certain limitations of our study:The small number of animals;The lack of blood samples from the animals that died during the experiment;The missing parameters determined directly from the kidneys;The fact that, in natural extracts, it is very unlikely to have the same individual polyphenol concentration and we did not conduct a phytochemical determination of the administered GE homogenate.

6. Conclusions {#sec6-pharmaceutics-11-00656}
==============

These results indicate that, despite promising antioxidant and protective theoretical effects, pomace grape extract did not have a protective effect on cisplatin-induced nephrotoxicity. This data further supports the disparity between the in vitro and in vivo actions of pomace grape extract. Moreover, this extract interacted with cisplatin and accentuated its toxic effect. Further investigations are needed to determine the mechanism and the exact substances through which the grape extract increases cisplatin-induced nephrotoxicity.
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![Experimental protocol and administered substances. Abbreviations are as follows: GEd, grape extract dose (1, 0.35 mL/kg b.w.; 2, 0.7 mL/kg b.w.); CIS, cisplatinum.](pharmaceutics-11-00656-g001){#pharmaceutics-11-00656-f001}

![Mean levels of urea and creatinine in the study groups. Abbreviations are as follows: GEd, grape extract dose; CIS, cisplatinum. Statistically significant differences are indicated by asterisks: \*\* *p* ≤ 0.001, \* *p* \< 0.05.](pharmaceutics-11-00656-g002){#pharmaceutics-11-00656-f002}

![Renal histological aspect of the control group (group 1). Description: Normal kidney histological aspect with slight congestion (HE, 400×).](pharmaceutics-11-00656-g003){#pharmaceutics-11-00656-f003}

![Renal histological aspect of the cisplatin group (group 4). Descriptions: (**A**, **B**, **C**) Partially and complete tubular epithelium necrosis, reactive modifications of the remaining epithelium, hyaline cylinders in the medulla (HE, 200×); (**D**) reactive epithelium and hyaline cylinders (HE, 200×).](pharmaceutics-11-00656-g004){#pharmaceutics-11-00656-f004}

![Renal histological aspect of groups receiving grape extract only before cisplatin (groups 5 and 6). Descriptions: (**A**) Group 5, GEd1 + CIS---marked stasis in the medulla, moderate stasis in the glomeruli, frequent intratubular hyaline cylinders in the cortical and medullar area, predominantly in the collector tubules, and tubular necrosis (15%) (HE, 100×); (**B**) Group 6, GEd2 + CIS---hyaline cylinders in the medulla and cortical area (HE, 50×).](pharmaceutics-11-00656-g005){#pharmaceutics-11-00656-f005}

![Renal histological aspect of groups receiving grape extract before and after cisplatin (groups 7 and 8). Descriptions: (**A**) Group 7, GEd1 + CIS + GEd1---interstitial congestion and hyaline cylinders (HE, 50×); (**B**) Group 7, GEd1 + CIS + GEd1---tubular epithelium dystrophy (HE, 200×); (**C**) Group 8, GEd2 + CIS + GEd2---tubular necrosis (HE, 200×).](pharmaceutics-11-00656-g006){#pharmaceutics-11-00656-f006}

![CIS means the plasmatic concentration in the study groups. Abbreviations are as follows: GEd, grape extract dose; CIS, cisplatinum.](pharmaceutics-11-00656-g007){#pharmaceutics-11-00656-f007}

pharmaceutics-11-00656-t001_Table 1

###### 

Mortality percentages in the study groups.

  Group               Mortality (%)
  ------------------- ---------------
  Control             0
  GEd1                0
  GEd2                0
  CIS                 50
  GEd1 + CIS          62.5
  GEd2 + CIS          75
  GEd1 + CIS + GEd1   37.5
  GEd2 + CIS + GEd2   87.5

Abbreviations are as follows: GEd, grape extract dose; CIS, cisplatinum.

pharmaceutics-11-00656-t002_Table 2

###### 

Tubular necrosis scores in the study group.

  Group             Score
  ----------------- -------
  Control           0
  GE1               0
  GE2               0
  Cis               2
  GE1 + Cis         2
  GE2 + Cis         3
  GE1 + Cis + GE1   1
  GE2 + Cis + GE2   3

Abbreviations are as follows: 0---no damage; 1---patchy isolated unicellular necrosis; 2---tubular necrosis \<25%; and 3---tubular necrosis between 25% and 50%; GEd, grape extract dose; CIS, cisplatinum.

pharmaceutics-11-00656-t003_Table 3

###### 

Total antioxidant capacity (TAC) results in the study groups.

  Group               TAC (mmol TR Eq/L)
  ------------------- --------------------
  Control             0.16
  GEd1                0.18
  GEd2                0.19
  CIS                 0.1
  GEd1 + CIS          0.19
  GEd2 + CIS          0.16
  GEd1 + CIS + GEd1   0.16
  GEd2 + CIS + GEd2   0.14

Abbreviations are as follows: GEd, grape extract dose; CIS, cisplatinum; TR Eq, Trolox equivalents.
